Allogene Therapeutics (ALLO) Free Cash Flow (2018 - 2026)

Allogene Therapeutics has reported Free Cash Flow for 9 years, with the latest figure at -$12.9 million in Q1 2026.

• Quarterly Free Cash Flow rose 75.59% year-over-year to -$12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$110.5 million (up 43.17% YoY) and the FY2025 annual result came in at -$150.5 million, up 23.2% from the prior year.
• Free Cash Flow improved to -$12.9 million in Q1 2026 per ALLO's latest filing, from -$27.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$12.9 million in Q1 2026 and troughed at -$70.1 million in Q1 2022.
• A 5-year average of -$48.5 million and a median of -$52.9 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2026: Free Cash Flow sank 42.1% in 2022, then surged 75.59% in 2026.
• Over 5 years, Free Cash Flow stood at -$64.1 million in 2022, then gained by 16.0% to -$53.8 million in 2023, then soared by 40.58% to -$32.0 million in 2024, then advanced by 13.39% to -$27.7 million in 2025, then soared by 53.35% to -$12.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$12.9 million, -$27.7 million, and -$30.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.